Helping Address Drug Shortages in America

At Fresenius Kabi, we work hand-in-hand with key healthcare stakeholders to help resolve current drug shortages and help prevent new ones. Learn more in this recent article in Becker’s Healthcare from our very own Lindsey Thomas, SVP of Marketing. [Learn More]

We’ve invested nearly $1 billion in pharmaceutical production facilities and distribution centers throughout the U.S.

Since 2017, Fresenius Kabi has invested nearly $1 billion to modernize and expand our advanced U.S. pharmaceutical production and distribution facilities. We are dedicated to strengthening the supply chain of care in and for the U.S. We have built a reputation as a trusted partner that can rapidly increase production levels in times of crisis and shortage.

We have been investing and taking action to create More Supply in America – building more filling and finishing capacity, agility, and redundancy to assure both speed and reliability of supply.

John Ducker, President and CEO of Fresenius Kabi USA, details the many ways in which Fresenius Kabi is expanding our capacity and capabilities in the U.S. to better serve our customers.

$800 million invested in 3 U.S. pharmaceutical production facilities in the last 5 years.

We delivered over 900 million units of injectable medicines in the past two years to U.S. hospitals and other sites of care.1 Our continued investments will allow us to nearly double U.S. production over the next five years. We are also building redundancies into our U.S. manufacturing and supply network to enable even more flexibility and resilience to react to future market needs.

74% of our pharmaceuticals for the U.S. are proudly formulated, filled and packaged in the U.S.2

Senior Vice President Brian Bulgarelli introduces the expansive capabilities of Fresenius Kabi’s three new built-to-suit distribution centers in the U.S.

Nearly $100 Million U.S. Supply Chain Expansion

With medicines and medical devices used every day in hospitals, clinics, blood centers and other sites all across the nation, Fresenius Kabi is expanding its distribution capabilities to bring us closer to our customers and to ensure greater efficiency in the distribution of our products.

This capacity expansion can help us more rapidly adapt to shifting customer needs. It helped us ramp up production of critical injectable medicines used by hospitals during the pandemic and enabled us to support America’s strategic national stockpile – as well as supporting America’s vaccine developers with vital pharmaceuticals.

1. 2022-2023 Data on file.
2. 2023 Data on file.
See how Fresenius Kabi is creating more manufacturing resilience in our 2024 Infographic [View PDF]  [Read Article]